Concurrent afatinib and stereotactic body radiotherapy in patient with oligometastatic EGFR-mutated non-small cell lung cancer: a case report and literature review
Year: 2025
Type: article
Study design: Case Report
Abstract: Background: -mutated patients with limited metastases. However, the efficacy and safety of concomitant second-generation TKIs and SBRT is still unknown. Case Description: G719X and L861Q, who after initial response, had developed intracranial progression during afatinib monotherapy. With local treatment for the brain metastasis, she continued to receive afatinib and then a concurrent consolidative lung SBRT. Until January 2023, the patient had achieved a PFS of 24 months and OS of 32 months without serious adverse events except for a grade 1 radiation pneumonitis after the lung SBRT. Conclusions: mutations with good tolerance. However, larger studies with longer follow-up, including randomized controlled trials, are needed to better define the response rates, survival outcomes, and toxicity profiles of this combined therapy. Additionally, further research is required to determine the optimal timing for introducing SBRT in conjunction with afatinib.
Source: AME Case Reports
DOI: 10.21037/acr-24-174
Authors: Lisi Sun, Dan Tao, Yuyu Lv, Chunyu Wang, Yue Xie, Wei Zhou
Institutions: Chongqing University, Chongqing Cancer Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4409353451